Complex | |
AACDB_ID: | 6548 |
PDBID: | 7SHU |
Chains: | CD_A |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 2.75 |
Reference: | 10.1038/s41467-021-27397-z |
Antibody | |
Antibody: | Omalizumab variant C02 Fv |
Antibody mutation: | Yes |
INN (Clinical Trial): | |
Antigen | |
Antigen: | Immunoglobulin heavy constant epsilon |
Antigen mutation: | No |
Durg Target: | P01854 |
Antibody
Heavy Chain: C
Mutation: G16D/S29N/A42T/I53V/D75G/R99K/S101N/H102N
>7SHU_C|Chain A[auth C], D[auth E]|omalizumab variant C02 VH|Homo sapiens (9606) SEVQLVESGGGLVQPDGSLRLSCAVSGYNITSGYSWNWIRQTPGKGLEWVASVTYDGSTNYNPSVKGRITISRDGSKNTFYLQMNSLRAEDTAVYYCAKGNNYFGHWHFAVWGQGTLVTVSSG |
Light Chain: D
Mutation: Q29K/Y33S/K48R
>7SHU_D|Chain B[auth D], E[auth F]|omalizumab variant C02 VL|Homo sapiens (9606) GSDIQLTQSPSSLSASVGDRVTITCRASKSVDSDGDSYMNWYQQKPGRAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKGGSENLYFQGGSGHHHHHHHH |
Antigen
Chain: A
Mutation: NULL
>7SHU_A|Chain C[auth A], F[auth B]|Immunoglobulin heavy constant epsilon|Homo sapiens (9606) GSCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNP |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
C: TYR27 SER31 GLY32 TYR33 TYR54 ASN100 ASN101 TYR102 PHE103 GLY104 TRP106 D: ASP32 GLY33 ASP34 TYR36 TYR53 TYR57 A: THR373 SER375 ARG376 ALA377 SER378 GLY379 LYS380 PRO381 GLU412 GLY413 GLU414 THR415 GLN417 ARG419 THR421 ALA428 MET430 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)